Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Apel­lis Phar­ma­ceu­ti­cals still can’t pin­point ex­act­ly what’s be­hind the rare cas­es of eye in­flam­ma­tion that’s been re­port­ed in pa­tients tak­ing its ge­o­graph­ic at­ro­phy drug Syfovre. And de­spite ex­ecs’ pledge to be trans­par­ent, the lack of an­swers is scar­ing in­vestors.

Both the Amer­i­can So­ci­ety of Reti­na Spe­cial­ists’ Re­search and Safe­ty in Ther­a­peu­tics Com­mit­tee (ASRS ReST com­mit­tee) — which first flagged the safe­ty con­cerns — and Apel­lis is­sued up­dates over the week­end on their re­spec­tive re­views, with slight dis­crep­an­cies. The ASRS ReST com­mit­tee con­firmed the dis­cov­ery of two more cas­es of reti­nal vas­culi­tis in the past two weeks, bring­ing the to­tal num­ber of cas­es to eight; mean­while, by Apel­lis’ count, there have been sev­en con­firmed cas­es of oc­clu­sive/non-oc­clu­sive reti­nal vas­culi­tis since Syfovre’s launch in March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER